Blueprint Medicines Corporation (NASDAQ: BPMC) and Asterias Biotherapeutics (NYSE:AST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Insider and Institutional Ownership

90.7% of Blueprint Medicines Corporation shares are owned by institutional investors. 3.4% of Blueprint Medicines Corporation shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Blueprint Medicines Corporation and Asterias Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Blueprint Medicines Corporation -388.91% -45.58% -34.66%
Asterias Biotherapeutics -2,762.03% -86.25% -66.19%

Analyst Ratings

This is a summary of current ratings and target prices for Blueprint Medicines Corporation and Asterias Biotherapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines Corporation 0 0 7 0 3.00
Asterias Biotherapeutics 0 0 2 0 3.00

Blueprint Medicines Corporation currently has a consensus price target of $55.88, indicating a potential downside of 10.27%. Asterias Biotherapeutics has a consensus price target of $12.00, indicating a potential upside of 275.00%. Given Asterias Biotherapeutics’ higher possible upside, analysts plainly believe Asterias Biotherapeutics is more favorable than Blueprint Medicines Corporation.

Earnings and Valuation

This table compares Blueprint Medicines Corporation and Asterias Biotherapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Blueprint Medicines Corporation $25.58 million 95.25 -$99.21 million ($3.07) -20.29
Asterias Biotherapeutics $6.15 million 26.00 -$29.79 million N/A N/A

Asterias Biotherapeutics has higher revenue, but lower earnings than Blueprint Medicines Corporation.

Summary

Blueprint Medicines Corporation beats Asterias Biotherapeutics on 8 of the 10 factors compared between the two stocks.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.